ALLIANCES - Financial Information Pertaining to Alliances (Pfizer) (Details) - USD ($) $ in Millions		12 Months Ended
		Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total Revenues		$ 46,385	$ 42,518	$ 26,145
Cost of products sold – Profit sharing	[1]	9,940	11,773	8,078
Other (income)/expense, net		(720)	(2,314)	938
Receivables		9,369	8,501
Accounts payable		2,949	2,713
Eliquis
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total Revenues		10,762	9,168	7,929
Collaborative Arrangement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total Revenues		11,556	9,979	10,541
Cost of products sold – Profit sharing		5,227	4,485	4,169
Other (income)/expense, net		(62)	(74)	(60)
Receivables		320	343
Accounts payable		1,229	1,093
Deferred income		330	366
Collaborative Arrangement | Pfizer
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total Revenues		10,762	9,168	7,929
Cost of products sold – Profit sharing		5,064	4,331	3,745
Other (income)/expense, net		(36)	(55)	(55)
Receivables		235	253
Accounts payable		1,195	1,024
Deferred income		264	300
Collaborative Arrangement | Pfizer | Eliquis
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total upfront, milestone and other licensing payments received to date		$ 884
Collaborative Arrangement | Pfizer | Eliquis | Maximum
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Percentage of reimbursement for development costs from alliance partner		60.00%
Collaborative Arrangement | Pfizer | Eliquis | Minimum
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Percentage of reimbursement for development costs from alliance partner		50.00%
Net product sales
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total Revenues		$ 45,055	41,321	25,174
Net product sales | Collaborative Arrangement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total Revenues		10,840	9,364	9,944
Net product sales | Collaborative Arrangement | Pfizer
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total Revenues		10,431	8,942	7,711
Collaborative Arrangement | Collaborative Arrangement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total Revenues		716	615	597
Collaborative Arrangement | Collaborative Arrangement | Pfizer
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total Revenues		$ 331	$ 226	$ 218

[1] Excludes amortization of acquired intangible assets.